TY - JOUR
T1 - Fluorine-18-α-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer
T2 - A clinicopathologic study
AU - Kaira, Kyoichi
AU - Oriuchi, Noboru
AU - Otani, Yoshimi
AU - Shimizu, Kimihiro
AU - Tanaka, Shigebumi
AU - Imai, Hisao
AU - Yanagitani, Noriko
AU - Sunaga, Noriaki
AU - Hisada, Takeshi
AU - Ishizuka, Tamotsu
AU - Dobashi, Kunio
AU - Kanai, Yoshikatsu
AU - Endou, Hitoshi
AU - Nakajima, Takashi
AU - Endo, Keigo
AU - Mori, Masatomo
PY - 2007/11/1
Y1 - 2007/11/1
N2 - Purpose: L-[3-18F]-α-Methyltyrosine ([18F]FMT) is an amino acid tracer for positron emission tomography (PET). We evaluated the diagnostic usefulness of [18F]FMT PET in non-small-cell lung cancer (NSCLC) patients. Tumor uptake of [18F]FMTwas compared with that of 2-[18F]-fluoro-2-deoxy-D-glucose ([18F]FDG) and correlated with L-type amino acid transporter 1 (LAT1) expression. Experimental Design: Fifty NSCLC patients were enrolled in this study, and a pair of PET study with [18F]FMT and [18F]FDG was done. LAT1 expression and Ki-67 labeling index of the resected tumors were analyzed by immunohistochemical staining. Results: For the primary tumor detection, [18F]FMT PET exhibited a sensitivity of 90% whereas the sensitivity for [18F]FDG PETwas 94%. For lymph node staging, the sensitivity and specificity of [ 18F]FMT PET were 57.8% and 100%, and those of [18F]FDG PET were 65.7% and 91%, respectively. The expression of LAT1 in squamous cell carcinoma and large cell carcinoma was significantly higher than that in adenocarcinoma. [18F]FMT uptake was also higher in squamous cell carcinoma and large cell carcinoma than in adenocarcinoma. Uptake of [ 18F]FMT in the tumor is closely correlated with LAT1 expression (ρ = 0.890). Conclusion: [18F]FMT PET had no false-positives in the detection of primary tumor and lymph node metastasis and could improve the diagnostic performance in NSCLC. Uptake of [18F]FMT correlated with the expression of LAT1 that showed a significant association with cellular proliferation.
AB - Purpose: L-[3-18F]-α-Methyltyrosine ([18F]FMT) is an amino acid tracer for positron emission tomography (PET). We evaluated the diagnostic usefulness of [18F]FMT PET in non-small-cell lung cancer (NSCLC) patients. Tumor uptake of [18F]FMTwas compared with that of 2-[18F]-fluoro-2-deoxy-D-glucose ([18F]FDG) and correlated with L-type amino acid transporter 1 (LAT1) expression. Experimental Design: Fifty NSCLC patients were enrolled in this study, and a pair of PET study with [18F]FMT and [18F]FDG was done. LAT1 expression and Ki-67 labeling index of the resected tumors were analyzed by immunohistochemical staining. Results: For the primary tumor detection, [18F]FMT PET exhibited a sensitivity of 90% whereas the sensitivity for [18F]FDG PETwas 94%. For lymph node staging, the sensitivity and specificity of [ 18F]FMT PET were 57.8% and 100%, and those of [18F]FDG PET were 65.7% and 91%, respectively. The expression of LAT1 in squamous cell carcinoma and large cell carcinoma was significantly higher than that in adenocarcinoma. [18F]FMT uptake was also higher in squamous cell carcinoma and large cell carcinoma than in adenocarcinoma. Uptake of [ 18F]FMT in the tumor is closely correlated with LAT1 expression (ρ = 0.890). Conclusion: [18F]FMT PET had no false-positives in the detection of primary tumor and lymph node metastasis and could improve the diagnostic performance in NSCLC. Uptake of [18F]FMT correlated with the expression of LAT1 that showed a significant association with cellular proliferation.
UR - https://www.scopus.com/pages/publications/35948940869
UR - https://www.scopus.com/inward/citedby.url?scp=35948940869&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-07-1294
DO - 10.1158/1078-0432.CCR-07-1294
M3 - Article
C2 - 17975149
AN - SCOPUS:35948940869
SN - 1078-0432
VL - 13
SP - 6369
EP - 6378
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 21
ER -
